CapsoVision (CV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting opened by Senior VP, Finance, with introductions of Board and executive team members, including recent appointments since 2024 and 2025.
Agenda included election of directors, ratification of auditors, closing remarks, and Q&A.
Board and executive committee updates
Board members introduced, highlighting new appointments since 2024 and 2025.
Senior VP, Sales, and independent auditor representative present.
Shareholder proposals
Proposal one: Election of directors Joanne Imperial, Michele Harari, and Henry King for terms until 2029.
Proposal two: Ratification of Baker Tilly as independent registered public accounting firm for 2026.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CapsoVision
- Q1 2026: $2.8M revenue, 48% margin, $7M net loss, $14M raised, ongoing going concern risk.CV
Q1 202614 May 2026 - Virtual meeting to re-elect directors, ratify auditor, and review governance and compensation.CV
Proxy filing28 Apr 2026 - AI-driven GI diagnostics firm registers 2.87M shares for resale after $14M private placement.CV
Registration filing17 Apr 2026 - 2025 revenue rose 15% to $13.6M, but net loss increased to $25.3M amid higher R&D and public costs.CV
Q4 202526 Mar 2026 - AI-powered capsule endoscopy drives growth and innovation in noninvasive GI screening.CV
Corporate presentation26 Mar 2026 - AI-driven capsule endoscopy platform expands into major GI markets, backed by strong financing.CV
The 38th Annual Roth Conference24 Mar 2026 - Offering 5.25M shares at $5.00–$5.50 to fund R&D; strong growth but ongoing losses and regulatory risks.CV
Registration Filing29 Nov 2025 - IPO seeks $22.8M for R&D and growth; revenue rising, but losses and risks remain high.CV
Registration Filing29 Nov 2025 - IPO seeks $22.8M to fund AI-driven GI diagnostics amid growth, losses, and regulatory risk.CV
Registration Filing29 Nov 2025